EcoR1 Capital, LLC
13F filer · CIK 0001587114Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$2.06BU.S. long equity reported on 13F
Positions309 new · 7 closed
Net flow last quarter-$967MBuys minus sells
Top 10 positions weight86.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202630 positions | |||||
| $600M | 29.19% | 32.17% | Not reported | Q1 2020 | |
| $532M | 25.86% | 27.08% | -33.3% | Q4 2019 | |
| $155M | 7.56% | 9.03% | Not reported | Q1 2026 | |
| $106M | 5.16% | 1.69% | +35.6% | Q4 2025 | |
| $78.6M | 3.82% | 7.68% | Not reported | Q3 2024 | |
| $75.8M | 3.68% | 1.44% | Not reported | Q3 2018 | |
| $72.9M | 3.54% | 6.49% | Not reported | Q2 2020 | |
| $63.9M | 3.11% | 8.97% | New | Q2 2026 | |
| $50M | 2.43% | 2.53% | Not reported | Q4 2015 | |
| $40M | 1.94% | 8.03% | Not reported | Q4 2023 | |
| $24M | 1.17% | 1.18% | +635.0% | Q1 2026 | |
| $24M | 1.17% | 8.59% | Not reported | Q2 2020 | |
| $23.1M | 1.12% | 0.22% | Not reported | Q4 2021 | |
| $21.5M | 1.05% | 3.52% | Not reported | Q3 2025 | |
| $21.4M | 1.04% | 0.81% | -50.0% | Q3 2024 | |
| $20M | 0.97% | 1.25% | Not reported | Q4 2025 | |
| $17.8M | 0.87% | 16.44% | +1458.3% | Q4 2014 | |
| $13.1M | 0.63% | 0.32% | -63.4% | Q3 2020 | |
| $11.8M | 0.58% | 1.61% | New | Q2 2026 | |
| $10.4M | 0.51% | 1.16% | New | Q2 2026 | |
| $9.56M | 0.46% | 1.35% | Not reported | Q1 2026 | |
| $8.13M | 0.40% | 0.36% | Not reported | Q4 2023 | |
| $6.96M | 0.34% | 1.24% | Not reported | Q1 2026 | |
| $6.78M | 0.33% | 0.78% | Not reported | Q2 2023 | |
| $6.55M | 0.32% | 0.26% | Not reported | Q3 2020 | |
| $6.05M | 0.29% | 0.11% | -63.3% | Q3 2021 | |
| $5.55M | 0.27% | 9.91% | New | Q2 2026 | |
| $2.28M | 0.11% | 1.81% | New | Q2 2026 | |
| $2.13M | 0.10% | Not reported | Not reported | Q1 2026 | |
| $318K | 0.02% | 0.13% | -92.5% | Q4 2025 | |
| Q1 2026Reported May 15, 202628 positions | |||||
| $575M | 24.41% | 31.42% | Not reported | Q1 2020 | |
| $437M | 18.55% | 27.14% | Not reported | Q4 2019 | |
| $323M | 13.69% | 2.77% | Not reported | Q2 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $238M | 10.11% | 3.88% | +92.6% | Q2 2021 |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $156M | 6.61% | 4.07% | Not reported | Q1 2020 |
| $86.3M | 3.66% | 9.03% | New | Q1 2026 | |
| $85.2M | 3.62% | 6.50% | Not reported | Q2 2020 | |
| $74.6M | 3.17% | 1.25% | +42.8% | Q4 2025 | |
| $66.1M | 2.80% | 1.44% | Not reported | Q3 2018 | |
| $53.6M | 2.27% | 7.94% | +7.0% | Q3 2024 | |
| $50M | 2.12% | 2.53% | Not reported | Q4 2015 | |
| $26.3M | 1.12% | 2.95% | -32.9% | Q2 2016 | |
| $25.6M | 1.09% | 8.14% | Not reported | Q4 2023 | |
| $25.3M | 1.07% | 3.53% | Not reported | Q3 2025 | |
| $23.2M | 0.98% | 1.63% | -63.4% | Q3 2024 | |
| $19M | 0.80% | 1.01% | Not reported | Q3 2020 | |
| $15.4M | 0.66% | 1.27% | Not reported | Q4 2025 | |
| $14.6M | 0.62% | 0.29% | Not reported | Q3 2021 | |
| $7.75M | 0.33% | 1.35% | New | Q1 2026 | |
| $7.65M | 0.32% | 1.21% | Not reported | Q2 2024 | |
| $7.02M | 0.30% | 1.24% | New | Q1 2026 | |
| $6.94M | 0.29% | 0.79% | Not reported | Q2 2023 | |
| $4.41M | 0.19% | 1.68% | +70.2% | Q4 2025 | |
| $3.26M | 0.14% | 0.16% | New | Q1 2026 | |
| $3.24M | 0.14% | 1.50% | Not reported | Q2 2023 | |
| $3.01M | 0.13% | 4.58% | -29.0% | Q4 2025 | |
| $2.03M | 0.09% | Not reported | New | Q1 2026 | |
| $471K | 0.02% | 1.17% | -82.6% | Q4 2014 | |
| Q4 2025Reported Feb 17, 202627 positions | |||||
| $605M | 27.44% | 30.78% | Not reported | Q1 2020 | |
| $382M | 17.33% | 28.12% | Not reported | Q4 2019 | |
| $290M | 13.16% | 2.78% | Not reported | Q2 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $200M | 9.06% | 4.49% | Not reported | Q1 2020 |
| CPCNTACentessa Pharmaceuticals PLC | $77.9M | 3.53% | 2.09% | +466.4% | Q2 2021 |
| $72.9M | 3.31% | 1.45% | Not reported | Q3 2018 | |
| $67M | 3.04% | 4.73% | Not reported | Q3 2024 | |
| $61.3M | 2.78% | 2.52% | -30.0% | Q4 2023 | |
| $55M | 2.50% | 6.83% | Not reported | Q2 2020 | |
| $54.5M | 2.47% | 2.53% | Not reported | Q4 2015 | |
| $49.8M | 2.26% | 4.52% | -47.1% | Q2 2016 | |
| $35.3M | 1.60% | 3.53% | Not reported | Q3 2025 | |
| $34.3M | 1.56% | 7.51% | Not reported | Q3 2024 | |
| $32.1M | 1.45% | 0.96% | New | Q4 2025 | |
| $28.7M | 1.30% | 1.45% | New | Q4 2025 | |
| $26.2M | 1.19% | 8.21% | Not reported | Q4 2023 | |
| $23.3M | 1.06% | 0.16% | New | Q4 2025 | |
| $20.8M | 0.94% | 0.34% | Not reported | Q4 2021 | |
| $17M | 0.77% | 2.15% | Not reported | Q3 2025 | |
| $15.7M | 0.71% | 6.78% | +497.2% | Q3 2021 | |
| $10.4M | 0.47% | 7.83% | Not reported | Q4 2014 | |
| $9.41M | 0.43% | 0.54% | New | Q4 2025 | |
| $8.63M | 0.39% | 0.28% | Not reported | Q1 2021 | |
| $4.49M | 0.20% | 1.04% | Not reported | Q4 2019 | |
| $4.3M | 0.20% | 7.41% | New | Q4 2025 | |
| $3.27M | 0.15% | 0.99% | New | Q4 2025 | |
| $1.99M | 0.09% | 0.63% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 202529 positions | |||||
| $392M | 18.83% | 30.57% | Not reported | Q1 2020 | |
| $241M | 11.58% | 28.58% | Not reported | Q4 2019 | |
| $233M | 11.17% | 6.42% | Not reported | Q4 2024 | |
| $225M | 10.79% | 2.81% | Not reported | Q2 2023 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $179M | 8.57% | 4.54% | Not reported | Q1 2020 |
| $90M | 4.32% | 1.48% | Not reported | Q3 2018 | |
| $89.3M | 4.29% | 9.53% | Not reported | Q3 2021 | |
| $80.7M | 3.87% | 6.92% | +315.8% | Q2 2020 | |
| APAPLSApellis Pharmaceuticals, Inc. | $78M | 3.74% | 2.73% | -71.0% | Q4 2017 |
| $72.1M | 3.46% | 8.61% | Not reported | Q2 2016 | |
| $57.7M | 2.77% | 2.53% | +60.8% | Q4 2015 | |
| $47.8M | 2.29% | 4.45% | Not reported | Q4 2023 | |
| $44.1M | 2.12% | 7.57% | Not reported | Q3 2024 | |
| $37.2M | 1.78% | 4.75% | +84.7% | Q3 2024 | |
| $34.4M | 1.65% | 0.33% | Not reported | Q4 2017 | |
| ABRNAMAvidity Biosciences, Inc. | $33.3M | 1.60% | 0.52% | +53.0% | Q2 2020 |
| $32.7M | 1.57% | 3.56% | New | Q3 2025 | |
| $22M | 1.06% | 8.60% | Not reported | Q4 2023 | |
| $15M | 0.72% | 0.30% | Not reported | Q2 2025 | |
| $14.7M | 0.70% | 2.16% | New | Q3 2025 | |
| MMTSRMetsera, Inc. | $14.2M | 0.68% | 0.26% | Not reported | Q1 2025 |
| CPCNTACentessa Pharmaceuticals PLC | $13.3M | 0.64% | 0.41% | Not reported | Q2 2021 |
| $8.55M | 0.41% | 0.86% | Not reported | Q4 2022 | |
| $8.21M | 0.39% | 7.95% | Not reported | Q4 2014 | |
| $7.72M | 0.37% | 1.00% | -79.2% | Q4 2015 | |
| $3.7M | 0.18% | 2.44% | New | Q3 2025 | |
| $3.56M | 0.17% | 0.29% | Not reported | Q1 2021 | |
| $3.13M | 0.15% | 1.21% | -82.9% | Q3 2021 | |
| $1.52M | 0.07% | 0.28% | New | Q3 2025 | |
Premium opens every quarter this fund has filed